Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from http://www.ncbi.nlm.nih.gov/pubmed/32039985 below:

Management and Outcome of Local Regrowths in a Watch-and-wait Prospective Cohort for Complete Responses in Rectal Cancer

Multicenter Study

Affiliations

• ¹ The Netherlands Cancer Institute, Department of Surgery, Amsterdam, The Netherlands.
• ² Champalimaud Foundation, Digestive Unit, Lisbon, Portugal.
• ³ GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.

• PMID: 32039985
• DOI: 10.1097/SLA.0000000000003738

Item in Clipboard

Multicenter Study

Marit E van der Sande et al. Ann Surg. 2021.

• ¹ The Netherlands Cancer Institute, Department of Surgery, Amsterdam, The Netherlands.
• ² Champalimaud Foundation, Digestive Unit, Lisbon, Portugal.
• ³ GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.

• PMID: 32039985
• DOI: 10.1097/SLA.0000000000003738

Item in Clipboard

Objective: To evaluate the management and oncological outcomes of rectal cancer patients with local regrowth in a watch-and-wait (W&W) program.

Background: Approximately 15%-30% of patients with a clinical complete response after (chemo) radiotherapy who undergo a W&W policy will experience a local regrowth. The risks of these local regrowths have not yet been fully established and main concerns include high postoperative morbidity, requirement of advanced surgery, and pelvic recurrence after regrowth treatment.

Methods: All patients with a local regrowth after an initial W&W approach between January 2005 and March 2018 were retrospectively identified from 2 cohorts of rectal cancer patients with a clinical complete response after (chemo) radiotherapy. Type and outcome of regrowth treatment were assessed. Oncological outcome was assessed using Kaplan-Meier estimates.

Results: Eighty-nine out of 385 patients developed a local regrowth after a median of 9 (interquartile range 7-14) months. Median follow-up time was 28 (interquartile range 19-41) months. Eighty-four (94%) patients underwent surgical treatment of the local regrowth: total mesorectal excision was performed in 58 out of 84 (69%) patients and local excision was performed in 26 (31%) patients. The 2-year local recurrence-free rate, distant metastasis-free rate, disease-free survival, and overall survival in the patients undergoing surgical treatment were 97.8%, 91.8%, 90.3%, and 98.4%, respectively.

Conclusion: The vast majority (97%) of patients with regrowth after a W&W policy were able to undergo treatment with curative intent for local regrowth. Uncontrolled pelvic disease was very rare.

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

PubMed Disclaimer

The authors report no conflicts of interest.

• Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.

  Renehan AG, Malcomson L, Emsley R, Gollins S, Maw A, Myint AS, Rooney PS, Susnerwala S, Blower A, Saunders MP, Wilson MS, Scott N, O'Dwyer ST. Renehan AG, et al. Lancet Oncol. 2016 Feb;17(2):174-183. doi: 10.1016/S1470-2045(15)00467-2. Epub 2015 Dec 17. Lancet Oncol. 2016. PMID: 26705854

• Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy.

  Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A, Widmar M, Ganesh K, Yaeger R, Cercek A, Weiser MR, Nash GM, Guillem JG, Temple LKF, Chalasani SB, Fuqua JL, Petkovska I, Wu AJ, Reyngold M, Vakiani E, Shia J, Segal NH, Smith JD, Crane C, Gollub MJ, Gonen M, Saltz LB, Garcia-Aguilar J, Paty PB. Smith JJ, et al. JAMA Oncol. 2019 Apr 1;5(4):e185896. doi: 10.1001/jamaoncol.2018.5896. Epub 2019 Apr 11. JAMA Oncol. 2019. PMID: 30629084 Free PMC article.

• [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].

  Huang Y, Huang SH, Chi P, Wang XJ, Lin HM, Lu XR, Ye DX, Lin Y, Deng Y. Huang Y, et al. Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):281-288. doi: 10.3760/cma.j.cn.441530-20200228-00096. Zhonghua Wei Chang Wai Ke Za Zhi. 2020. PMID: 32192308 Chinese.

• A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis.

  Dossa F, Chesney TR, Acuna SA, Baxter NN. Dossa F, et al. Lancet Gastroenterol Hepatol. 2017 Jul;2(7):501-513. doi: 10.1016/S2468-1253(17)30074-2. Epub 2017 May 4. Lancet Gastroenterol Hepatol. 2017. PMID: 28479372 Review.

• Outcome and Salvage Surgery Following "Watch and Wait" for Rectal Cancer after Neoadjuvant Therapy: A Systematic Review.

  Kong JC, Guerra GR, Warrier SK, Ramsay RG, Heriot AG. Kong JC, et al. Dis Colon Rectum. 2017 Mar;60(3):335-345. doi: 10.1097/DCR.0000000000000754. Dis Colon Rectum. 2017. PMID: 28177997 Review.

• Beneficiaries of radical surgery among clinical complete responders to neoadjuvant chemoradiotherapy in rectal cancer.

  Zhang S, Zhang R, Li RZ, Wang QX, Chang H, Ding PR, Li LR, Wu XJ, Chen G, Zeng ZF, Xiao WW, Gao YH. Zhang S, et al. Cancer Sci. 2021 Sep;112(9):3607-3615. doi: 10.1111/cas.15039. Epub 2021 Jul 21. Cancer Sci. 2021. PMID: 34146368 Free PMC article.

• Is clinical complete response as accurate as pathological complete response in patients with mid-low locally advanced rectal cancer?

  Shadmanov N, Aliyev V, Piozzi GN, Bakır B, Goksel S, Asoglu O. Shadmanov N, et al. Ann Coloproctol. 2025 Feb;41(1):57-67. doi: 10.3393/ac.2024.00339.0048. Epub 2025 Feb 28. Ann Coloproctol. 2025. PMID: 40044112 Free PMC article.

• Chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series.

  Asoglu O, Bulut A, Aliyev V, Piozzi GN, Guven K, Bakır B, Goksel S. Asoglu O, et al. World J Surg Oncol. 2022 Nov 10;20(1):358. doi: 10.1186/s12957-022-02816-7. World J Surg Oncol. 2022. PMID: 36352416 Free PMC article.

• Role of Local Excision for Suspected Regrowth in a Watch and Wait Strategy for Rectal Cancer.

  Geubels BM, Meyer VM, van Westreenen HL, Beets GL, Grotenhuis BA, On Behalf Of The Dutch Watch And Wait Consortium. Geubels BM, et al. Cancers (Basel). 2022 Jun 23;14(13):3071. doi: 10.3390/cancers14133071. Cancers (Basel). 2022. PMID: 35804843 Free PMC article.

• Advantageous factors of R0 curative conversion esophagectomy and the optimal extent of lymphadenectomy after induction therapy for cT4b thoracic esophageal cancer.

  Ohkura Y, Ueno M, Udagawa H. Ohkura Y, et al. Ann Gastroenterol Surg. 2020 Dec 11;5(2):204-214. doi: 10.1002/ags3.12416. eCollection 2021 Mar. Ann Gastroenterol Surg. 2020. PMID: 33860140 Free PMC article.

1. 1. Paun BC, Cassie S, MacLean AR, et al. Postoperative complications following surgery for rectal cancer. Ann Sur 2010; 251:807–818.
2. 1. Lange MM, Marijnen CA, Maas CP, et al. Risk factors for sexual dysfunction after rectal cancer treatment. Eur J Cancer 2009; 45:1578–1588.
3. 1. Bregendahl S, Emmertsen KJ, Lous J, et al. Bowel dysfunction after low anterior resection with and without neoadjuvant therapy for rectal cancer: a population-based cross-sectional study. Colorectal Dis 2013; 15:1130–1139.
4. 1. Andersson J, Abis G, Gellerstedt M, et al. Patient-reported genitourinary dysfunction after laparoscopic and open rectal cancer surgery in a randomized trial (COLOR II). Br J Surg 2014; 101:1272–1279.
5. 1. Bregendahl S, Emmertsen KJ, Lindegaard JC, et al. Urinary and sexual dysfunction in women after resection with and without preoperative radiotherapy for rectal cancer: a population-based cross-sectional study. Colorectal Dis 2015; 17:26–37.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3